Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Henrı́quez, I.; Roach, Mack; Morgan, Todd M; Bossi, Alberto; Gómez, Junior; Abuchaibe, Oscar; Couñago, Felipe

doi:10.3390/biomedicines9091247

Cited by 47 publications

(27 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, among patients with metastatic disease, a substantial proportion will develop metastatic castration-resistant prostate cancer (mCRPC), which is not sensitive to androgen deprivation therapy. Therefore, the long-term prognosis for patients with mCRPC is extremely poor ( Henríquez et al, 2021 ). On that account, it is critical to unearth the mechanism of metastasis of prostate cancer, which may assist us in predicting the prognosis of patients and forming a desirable therapeutic regimen.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

Xiao

Chen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Prostate cancer is one of the most common malignancies in males. Despite the recent development of advanced diagnostic platforms and treatment, patients with metastatic disease still have a poor five-year survival rate. Cancer metastasis is correlated with the characteristics of the tumor microenvironment and is significantly associated with patient prognosis. In this study, we obtained mutated genes with significant differences between primary and metastatic prostate cancer from the COSMIC database. Unsupervised consensus clustering was used based on the 1,051 genes obtained, and two PCa clusters were identified, which exhibited different prognostic outcomes and immune characteristics. Next, we generated a scoring system and evaluated the prognostic value of riskscore and its potential to aid treatment decisions in clinical practice. The riskscore could be applied to predict patients’ response to immunotherapy and sensitivity to Docetaxel. In conclusion, this study performed an integrated analysis of mutated genes between primary and metastatic prostate cancer and provides a novel assessment scheme to precisely select treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

Xiao

Chen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…There are still many unanswered questions regarding the use of PARPi in PCa, including who would benefit more from a genetic study and when is the best time to use it in the natural evolution of the disease [ 9 ]. These questions make it necessary to deepen the knowledge of these drugs to find potential ways to maximize their clinical effectiveness.…”

Section: Introductionmentioning

confidence: 99%

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of synthetic lethality, have been approved for prostate cancer. In addition, it is also the first time that genetic mutation tests have been included in the therapeutic algorithm of this disease, representing a significant step forward for precision and personalized treatment of prostate cancer. The objectives of this review are: (1) understanding the mechanism of action of PARPi in monotherapy and combinations; (2) gaining insights on patient selection for PARPi; (3) exposing the pivotal studies that have allowed its approval, and; (4) offering an overview of the ongoing trials. Nevertheless, many unsolved questions remain, such as the number of patients who could potentially benefit from PARPi, whether to use PARPi in monotherapy or in combination, and when is the best time to use them in advanced or localized disease. To answer these and other questions, many clinical trials are underway. Some of them have recently demonstrated promising results that may favor the introduction of new combinations in metastatic castration-resistant prostate cancer.

show abstract

“…5–7 With many mCRPC treatments approved in the last decade and more on the way, there is an urgent need for real-time and tumor biomarkers to help guide the selection. 8 …”

Section: Introductionmentioning

confidence: 99%

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer

Jang¹,

Rauterkus²,

Vaishampayan³

et al. 2022

OTT

View full text Add to dashboard Cite

Prostate cancer is one of the most common malignancies in men. Over time, it can metastasize and become lethal once it exhausts hormonal therapies and transitions into castration-resistant prostate cancer (CRPC). Several therapies have been recently approved for advanced prostate cancer, but identifying biomarkers for current treatments and searching for more effective treatments are urgently needed. Liquid biopsy is a powerful tool for isolating genetic material, proteins, and whole tumor cells from the blood. In recent decades, this technology has rapidly advanced, allowing for better insights into the pathogenesis and treatment response in different stages of prostate cancer. In this review, we summarize important clinical studies involving liquid biopsies in prostate cancer with a focus on advanced disease, notably regarding circulating tumor DNA, circulating tumor cells, and exosomes. We highlight the progress and the challenges that still exist for these technologies. Finally, we discuss promising avenues that will further expand the importance of liquid biopsy in the care for prostate cancer patients.

show abstract

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Cited by 47 publications

References 53 publications

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer

Contact Info

Product

Resources

About